Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced‐stage Hodgkin lymphoma in older patients

作者：Paul J. Bröckelmann, Boris Böll, Daniël G. M. Molin, Gundolf Schneider, Sirpa Leppä, Julia Meißner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, Michael Fuchs, Janina Jablonski, Dennis A. Eichenauer, Bastian von Tresckow, Wolfram Klapper, Carsten Kobe, Peter Borchmann, Alexander Fosså · 发表于：HemaSphere · 年份：2025 · DOI：10.1002/hem3.70190 · 被引用次数：2 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Lung Cancer Treatments and Mutations

Historically, the outcomes among older patients with classic Hodgkin lymphoma (HL) have been inferior compared to younger patients, and 80% of HL-related deaths occur in patients ≥ 55 years of age at diagnosis.1 These inferior outcomes are in part attributable to comorbidities and frailty, resulting in poorer tolerability of standard multi-agent chemotherapies such as doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).2 Even if treatment is administered at standard relative dose intensities, lower progression-free survival (PFS) and overall survival (OS) are observed,3, 4 especially in patients with high comorbidity burden or impaired activities of daily living.5, 6 In light of demographic changes and increased life expectancy in many countries, the growing group of older patients hence constitutes a growing unmet need.7 Recently, encouraging results were reported from subgroup analyses and a Phase II trial incorporating either brentuximab vedotin (BV) or nivolumab into first-line treatment.8 Prospective clinical trials specifically designed to explore novel treatment options specifically in older HL patients remain however scarce. Moreover, patient-reported health-related quality of life (HRQoL) data in patients ≥ 60 years of age remain scarce to absent. Understanding the baseline HRQoL status and treatment-related trajectories in this patient population hence is of immediate interest. In the international German Hodgkin Study Group (GHSG)-NLH intergroup Phase II BV...